Mitral annular disjunction

Article written and reviewed by Dr Luca Moretti

Mitral annular disjunction, referred to in the international literature as mitral annular disjunction or MAD, is an abnormality of continuity between the junction of the posterior mitral leaflet, the left atrial wall and the basal ventricular myocardium. Instead of being directly supported by myocardium, the insertion point appears separated and moves excessively during systole. The finding is described mainly along the posterolateral annulus, whereas the anterior mitral-aortic fibrous continuity has different anatomy.

Contemporary interest arises from its association with mitral valve prolapse, myxomatous disease, abnormal annular motion, inferobasal or papillary fibrosis and ventricular arrhythmias. Association does not imply necessary causality. MAD may be an incidental finding, prolapse may be arrhythmic without disjunction, and most people with MAD do not experience sudden death. The finding becomes meaningful only within a complete clinical and rhythm phenotype.

The definition remains difficult because of imaging planes, cardiac-cycle phase and nonuniform terminology. Billowing of the posterior leaflet may simulate a systolic separation that disappears in diastole, currently termed pseudo-MAD in part of the literature. Distinguishing a persistent anatomical discontinuity from this functional effect avoids overdiagnosis, unwarranted alarm and incomparable epidemiological studies.

Dynamic anatomy, true MAD and pseudo-disjunction

The posterior mitral annulus is not a complete rigid fibrous structure, but a three-dimensional region in which the leaflet, atrial tissue, atrioventricular groove fat and ventricular myocardium are continuous with one another. Under normal conditions, basal myocardium supports the posterior hinge and the annulus assumes a dynamic saddle shape; in mitral annular disjunction, by contrast, part of the hinge is displaced atrially relative to the top of the myocardium.

The conventional measurement is the distance, at end-systole or at the phase of maximal separation, between the posterior leaflet insertion and the upper border of ventricular myocardium. It should be perpendicular to the annulus and obtained in a plane that truly traverses the inferolateral wall. A single two-dimensional section does not define circumferential extent: a long but focal distance and a shorter, extensive separation are not equivalent anatomies.

The EHRA consensus described MAD as systolic separation, reflecting the phase in which it is most evident. More recent dynamic studies distinguish true MAD, recognizable in diastole as well as an anatomical discontinuity, from pseudo-MAD, visible only in systole because the billowing posterior leaflet becomes apposed to the atrial wall. Terminology is evolving; the report should specify what is observed rather than turning a research definition into ontological certainty.

Pseudo-MAD occurs when a redundant leaflet becomes apposed to the atrial wall during systole and creates a line that can be mistaken for the true hinge. When the anatomical insertion is followed frame by frame, however, continuity with the ventricle remains recognizable and becomes evident again in diastole. Measuring the base of the apposed leaflet as the disjunction space therefore overestimates both length and prevalence; high temporal resolution, zoom and comparison between systole and diastole are essential to avoid this error.

MAD is not synonymous with a dilated annulus. Dilation increases diameters and reduces coaptation; disjunction alters annular-ventricular support. The two conditions may coexist in Barlow disease and contribute to regurgitation through different pathways. MAD is also not equivalent to annular calcification, which stiffens the junction and belongs to a different degenerative-metabolic process.

Associated dynamic findings include curling, an accentuated outward systolic motion of the inferobasal wall and annulus, interpreted as an expression of abnormal mechanics with increased papillary traction. Curling and MAD are related but describe different phenomena: the former is dynamic deformation, the latter an anatomical relationship. Keeping the two signs separate is important because their prognostic significance is still being validated.

There is still no universally accepted minimum threshold for defining disjunction. Some studies consider any visible separation, others require distances of several millimeters or analyze maximal length; moreover, echocardiographic resolution, magnetic resonance slice thickness and the selected cardiac phase introduce a gray zone. A measurement reported to the decimal therefore does not eliminate biological and technical uncertainty: location, method and degree of confidence are part of the finding.

Circumferential extent is also heterogeneous. Disjunction tends to be greater near P1-P2 and posterolateral regions, but it may appear in several segments. Three-dimensional reconstruction or multiple magnetic resonance planes prevent a negative section from excluding a focal finding. It has not yet been established which combination of length and extent best predicts events.

Relationship with prolapse, fibrosis and arrhythmias

Disjunction is more frequent in myxomatous phenotypes, especially bileaflet prolapse and Barlow disease. Prevalence estimates vary widely because populations, methods, thresholds and definitions differ. Its presence in people without prolapse demonstrates that it is neither necessary nor sufficient for degenerative valve disease. Interpretation should avoid circular reasoning in which every redundant leaflet proves MAD and every MAD proves an arrhythmic syndrome.

The pathophysiological model proposes that annular hypermobility and prolapse exert repeated traction on the papillary muscles and inferolateral myocardium. Mechanical stress could generate focal fibrosis, electrical heterogeneity and triggers arising from the papillary apparatus or annulus. Pathology and magnetic resonance studies have identified replacement fibrosis in these regions in some patients with arrhythmias, but the causal sequence has not been demonstrated in all patients with MAD.

Premature ventricular complexes often arise from the papillary muscles, fascicles or outflow tract. Polymorphic morphology, couplets, rapid nonsustained or sustained ventricular tachycardia and ventricular fibrillation carry increasing weight. A high ectopic burden can cause or worsen ventricular dysfunction; conversely, a few monomorphic premature beats in an asymptomatic person do not define arrhythmic mitral valve prolapse.

The consensus defines an arrhythmic mitral valve prolapse phenotype when MVP, with or without MAD, is associated with frequent or complex ventricular arrhythmias in the absence of another evident arrhythmic substrate. It is a diagnosis of exclusion. Ischemic heart disease, cardiomyopathy, myocarditis, sarcoidosis, channelopathies and drug toxicity should be considered, especially when scar or arrhythmias do not follow the papillary-inferolateral distribution.

Markers that warrant greater attention include unexplained syncope, sustained or rapid nonsustained ventricular tachycardia, complex ectopy, inferior T-wave inversion, redundant bileaflet prolapse, marked MAD, enlarged left atrium, reduced ejection fraction and late gadolinium enhancement in the papillary muscles or perianular wall. No single finding has sufficient predictive value to become a binary test.

Severity of mitral regurgitation retains its own prognostic significance and should not be absorbed into the arrhythmic discussion. Important regurgitation promotes dilation, atrial fibrillation, heart failure and mortality even without ventricular arrhythmias, while malignant events have been reported, albeit in a small minority, even with nonsevere regurgitation. Assessment should therefore proceed along two parallel axes: hemodynamic consequences of valve disease and electrical risk.

Postsurgical cohorts suggest that MAD may be associated with residual arrhythmic risk and that repair does not automatically erase the substrate. This observation is consistent with persistent fibrosis or reentrant circuits but is subject to selection and variable definitions. It is not correct to conclude that surgery is ineffective or to propose it as universal arrhythmic prophylaxis: the primary indication remains severe regurgitation according to guidelines.

Arrhythmias may also depend on regurgitant volume and remodeling, not only on traction. Dilation and wall stress alter electrophysiology, while reduced ejection fraction introduces its own indications. Separating papillary triggers, fibrotic substrate and consequences of regurgitation is difficult but clinically decisive: each mechanism responds differently to ablation, surgery or defibrillator therapy.

The so-called pickelhaube sign, a high-velocity systolic spike on tissue Doppler of the lateral annulus, has been associated with an arrhythmic phenotype in small cohorts. It remains an exploratory marker sensitive to sampling and global motion. It should not be used as a stand-alone test or cited without describing documented arrhythmias and examination quality.

Echocardiography, magnetic resonance imaging and rhythm monitoring

Parasternal long-axis transthoracic echocardiography is the starting point. With zoom of the posterior junction, the true hinge is identified and its distance from the myocardium is measured in the appropriate frame; apical views allow more medial and lateral sites to be explored, but the saddle shape and oblique planes can generate errors. The report should therefore specify image quality, cardiac phase and measurement site.

The assessment is dynamic and follows the hinge from opening to closure. Persistence of separation in diastole supports anatomical discontinuity; appearance exclusively in systole requires a search for pseudo-MAD. Three-dimensional echocardiography can define circumferential extent, while transesophageal imaging improves leaflet and repair mapping. No modality eliminates the need to recognize artifacts.

The report includes the type and extent of prolapse, leaflet thickness and redundancy, flail segments, regurgitation, annular dimensions, curling, ventricular and atrial size. Longitudinal strain and mechanical dispersion may indicate heterogeneous function, but there are no universally validated thresholds for deciding on a defibrillator or surgery. They should be interpreted as complementary information.

Cardiac magnetic resonance imaging provides broad multiplanar coverage, measures MAD distance and extent and characterizes the myocardium. Late gadolinium enhancement detects replacement fibrosis; T1 mapping and extracellular volume explore diffuse abnormalities. The spatial resolution of thin papillary muscles and partial-volume effects require caution: an equivocal signal is not equivalent to a definite arrhythmogenic scar.

Cardiac magnetic resonance is particularly indicated after cardiac arrest or ventricular tachycardia, in the presence of syncope, complex arrhythmias, reduced function or discordant echocardiography. It also quantifies regurgitation and volumes. CT visualizes the annulus and its relationship to coronary arteries but is not the first choice for a fibrotic substrate; it may identify MAD incidentally during structural planning.

A 12-lead ECG looks for inferior T-wave abnormalities, intervals and premature ventricular complex morphology. At least 24-hour Holter monitoring is reasonable in prolapse with suspected arrhythmic phenotype; longer duration improves estimation of variability and burden. Rare symptoms or unexplained syncope may require prolonged external recorders or an implantable loop recorder selected according to pretest probability.

Exercise testing evaluates adrenergic arrhythmias and capacity, but an arrhythmia occurring only during exercise is not automatically specific to MAD. Electrophysiological study has limited sensitivity as a screening test for sudden death in prolapse and is used for selected questions. Genetic testing is not routine for isolated MAD; it is indicated if the phenotype suggests cardiomyopathy or an inherited syndrome.

Diagnosis should finally make uncertainty explicit. A finding of a few millimeters near the limit of resolution should not be rounded up into a syndrome. Repeating high-quality imaging, comparing systole with diastole and obtaining expert review may be more informative than an indiscriminate cascade of tests. Reproducibility is part of clinical accuracy.

When counting premature ventricular complexes, day-to-day variability makes a single Holter insufficient when symptoms and results diverge. Multi-day recordings increase sensitivity for nonsustained tachycardia and estimate burden more accurately. The report should indicate rate, duration, morphologies and relationship to symptoms, because "ventricular ectopy present" does not distinguish a common finding from a high-risk signal.

Risk stratification and treatment of arrhythmias

Stratification starts with events already documented. Resuscitated cardiac arrest, ventricular fibrillation or sustained ventricular tachycardia without a reversible cause are established indications for secondary prevention with a defibrillator according to arrhythmia guidelines. The presence of MAD may explain the context but does not change the strength of the clinical event.

In primary prevention, there is neither a validated MAD-specific score nor a MAD length that automatically mandates ICD implantation. Syncope, arrhythmia type and rate, burden, ventricular function, fibrosis and the valvular phenotype should be integrated; the EHRA consensus identifies scenarios in which a defibrillator may be reasonable, but acknowledges that the evidence remains observational. The decision therefore requires electrophysiological expertise and explicit discussion of the risks of shocks, infection and leads.

Beta-blockers may reduce palpitations and some premature beats; flecainide or other antiarrhythmic agents are selected after structural and proarrhythmic contraindications have been excluded. Amiodarone reduces arrhythmias but has cumulative toxicity and is not an innocuous solution for young minimally symptomatic patients. Drug therapy targets symptoms and arrhythmic burden; no particular drug has been shown to abolish the risk of sudden death associated with the phenotype.

Catheter ablation is considered for refractory symptomatic ectopy, ectopy-induced cardiomyopathy, recurrent tachycardia or appropriate shocks. Papillary foci are mobile, deep and difficult to stabilize; intracardiac imaging, mapping and different energy sources may be necessary. Recurrence is not uncommon when multiple morphologies or a diffuse substrate are present.

Surgical correction of regurgitation follows symptoms, severity and ventricular consequences. Annuloplasty restores support and may reduce mechanical stress, but studies do not demonstrate uniform prevention of arrhythmias. In patients with a valve indication and documented arrhythmias, the plan also includes postoperative monitoring; disappearance of regurgitation does not justify automatically stopping surveillance.

Physical exercise is individualized. A person with isolated MAD, normal imaging and no significant arrhythmias should not be equated with someone who has syncope, fibrosis and complex tachycardia. In competitive sports, assessment considers intensity, phenotype, exercise testing and monitoring. Recommendations and follow-up should avoid both generalized restrictions and reassurance without documentation.

Typical vasovagal syncope with prodromes has a different significance from abrupt loss of consciousness during exertion or while seated. Reconstruction includes witness accounts, duration, recovery, trauma and ECG; orthostatic hypotension and neurological causes should be considered. Labeling every syncopal episode in a patient with MAD as arrhythmic increases unnecessary procedures, while ignoring an unexplained episode may miss the most important clinical marker.

Follow-up and risk communication

Surveillance depends on the baseline profile. In low-risk patients, symptoms, ECG, regurgitation and structure are reassessed at proportionate intervals; new events modify the plan. Increasing palpitations, syncope, a family history of sudden death or increasing ectopy justify earlier monitoring. Frequency is not determined by length in millimeters alone.

A patient with an arrhythmic phenotype requires continuity between valve cardiology, imaging and electrophysiology. Follow-up assesses burden, new morphologies, ventricular function, fibrosis and progression of regurgitation. After ablation, surgery or ICD implantation, the previous trajectory remains informative: an intervention changes risk but does not rewrite clinical history.

Risk communication requires particular care because the term MAD is often linked online to sudden death. It is more accurate to explain that the absolute risk of malignant events in prolapse is low and concentrated in a minority of patients and that currently available markers are imperfect. Presenting uncertainty in graded terms together with a concrete follow-up plan avoids both absolute reassurance and unwarranted alarm.

Family history should be contextualized. Sudden unexplained death at a young age warrants documentary reconstruction and may guide family assessment; ischemic events at older age do not prove an inherited syndrome. Screening of relatives is not standardized for isolated MAD, but echocardiography and ECG may be reasonable when prolapse appears familial or the phenotype is severe.

Research still needs to standardize the definition, measurement and outcomes. Studies that mix true and pseudo-MAD or use different thresholds generate incompatible prevalence and risk estimates. Prospective registries with core laboratories, systematic monitoring and magnetic resonance imaging can separate the value of disjunction from that of prolapse, regurgitation and fibrosis.

Longitudinal follow-up of MAD also requires caution: a difference of a few millimeters between examinations may depend on the imaging plane, pressure or selected frame and may not represent anatomical progression. Direct comparison of images, use of the same modality and greater weight placed on new symptoms, arrhythmias or fibrosis prevents measurement variability from being turned into false disease progression.

In practice, MAD is neither a harmless curiosity nor an arrhythmic sentence. It is a phenotypic modifier that requires anatomical precision and, when associated with clinical signals, proportionate rhythm evaluation. The best result is to avoid two opposite errors: overlooking a substrate in patients with syncope or complex arrhythmias and indefinitely medicalizing someone who has only an equivocal finding and no other indicator.